Behavioral Pediatrics: Mental Health and Management. Fifth Edition

$230.00

Donald E. Greydanus, MD, Dr HC (Athens), FAAP, FIAP (HON) – Professor & Founding Chair, Department of Pediatric & Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA
Dilip R. Patel, MD, MPH, MBA – Professor & Chair, Department of Pediatric & Adolescent Medicine, Western Michigan University, Homer Stryker MD School of Medicine, Kalamazoo, MI
Ahsan Nazeer, MD – Professor, Division Chief, Child and Adolescent Psychiatry, Sidra Medical and Research Center, Qatar Foundation, Doha, Qatar
Roger W. Apple, PhD – Director, Division of Pediatric Psychology, Department of Pediatric and Adolescent Medicine, Homer Stryker MD School of Medicine, Western Michigan University, Kalamazoo, MI USA
Joav Merrick, MD, MMedSci, DMSc – Professor of Pediatrics at the Division of Pediatrics, Hadassah Hebrew University Medical Center, Mt Scopus Campus, Jerusalem, Israel, Kentucky Children’s Hospital, University of Kentucky, Lexington, United States and Professor of Public Health at the Center for Healthy Development, School of Public Health, Georgia State University, Atlanta, United States, the former Medical Director of the Division for Intellectual and Developmental Disabilities, Ministry of Social Affairs and Social Services, Jerusalem and the Founder and Director of the National Institute of Child Health and Human Development, Israel.

Series: Pediatrics, Child and Adolescent Health
BISAC: MED102000; MED057000
DOI: https://doi.org/10.52305/GBFG5410

Pediatricians can provide a wide variety of care to children and adolescents with complex disorders, depending on their training as well as interests, but they need to work closely with professionals in psychiatry and psychology when dealing with complex issues in mental health disorders. Behavioral health screening is therefore an important task of pediatricians and behavioral pediatricians as they evaluate their pediatric patients. Section one looks at what is called special issues in mental health that include suicide/self-harm in pediatrics, childhood-onset schizophrenia, child abuse/maltreatment, mental health issues of chronic disorders (i.e., diseases of the cardiovascular system, the kidneys and the liver), and behavioral/emotional effects of COVID-19 on children/adolescents. Section two covers various aspects of substance use disorders (SUD) that include SUD neurobiology, substance use/abuse in adolescents, an overview on cannabis, psychosocial treatments of SUDs, pharmacologic management of SUDs, and pharmacology of tobacco abuse. Section three provides a critical look at mental health management that includes psychotherapeutic interventions (i.e., children, adolescents and families), behavioral/cognitive behavioral therapies and principles of psychopharmacologic management in pediatric persons.

Table of Contents

Preface

Section One: Special Issues

Chapter 1. Suicide and self-harm in children and adolescents
Finza Latif, MD, Karen Lim, MD and Ahsan Nazeer, MD
Child and Adolescent Mental Health Services (CAMHS), Sidra Medicine, Doha, Qatar

Chapter 2. Psychotic disorders in children and adolescents
Burhan Ahmed Khan1, MD, Zeeshan Mansuri2, MD, MPH and Zheala Qayyum3, MD MMSc
1Institute for Technology in Psychiatry, McLean Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
2Child and Adolescent Psychiatry Fellow, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
3Child and Adolescent Psychiatry, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Chapter 3. Recognizing and treating the emotional and behavioral effects of child maltreatment
Olga Jablonka, PhD, Chanelle Coble, MD and Vincent J Palusci, MD, MS
Frances L Loeb Child Protection and Development Center, Bellevue Hospital Center, New York University Grossman School of Medicine, New York, United States of America

Chapter 4. Mental health and chronic disease: Issues in cardiovascular disease
Nelli El-Ghazal1, PhD, Christina Helen Vlahos2, PhD, and Ahsan Nazeer2, MD
1Child and Adolescent Psychiatry, Department of Psychiatry, Sidra Medicine, Doha
2Department of Psychiatry, Weil Cornell Medical School, Doha, Qatar

Chapter 5. Mental health considerations in renal disease
Salma Malik, MD, Stephanie Kuntz, DO, Sumayya Ayaz, MD, and Ahsan Nazeer, MD
Child and Adolescent Psychiatry, Department of Psychiatry, Institute of Living, Hartford, Connecticut, United States and Child and Adolescent Psychiatry, Department of Psychiatry, Sidra Medicine, Doha, Qatar

Chapter 6. The pediatric liver: Mental health considerations
Christina Helen Vlahos, PhD and Muhammad Waqar Azeem, MD
Department of Psychiatry, Weil Cornell Medical School, Doha, Qatar

Section Two: Perspectives of substance use disorders

Chapter 7. Behavioral/emotional effects of COVID-19 on children and teens
Prasanth Narahari1, MD, Myrtha Gregoire-Bottex2, MD, Meredith Bishop3, MA, Cristina Matheus1, MD and Monica Dowling4, PhD
1Holtz Children’s Hospital/Jackson Memorial Hospital, Miami, Florida
2
Pediatric Cystic Fibrosis Program, Pediatric Pulmonology, Department of Pediatrics. University of Miami Miller School of Medicine, Miami, Florida
3University of Miami Miller School of Medicine, Mailman Center for Child Development, Miami, Florida
4Pediatrics, University of Miami Miller School of Medicine. Mailman Center for Child Development, Miami, Florida, United States of America

Chapter 8. Neurobiology of substance use disorders
Nehdia Hashemi1, MD, Nazish Imran2, MRCPsych, Muhammad Waqar Azeem3, MD and Ahsan Nazeer3, MD
1Western Michigan University, Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America
2Department of Psychiatry, King Edward Medical University, Lahore, Pakistan
3Department of Psychiatry, Division of Child and Adolescent Psychiatry, Sidra Medicine, Doha, Qatar

Chapter 9. Substance use and abuse in adolescents: An overview
Donald E Greydanus1, MD, DrHC(Athens), Prerna Kukreti2, MD and Harish K Pemde3, MD
1Department of Pediatric and Adolescent Medicine, Western Michigan University
Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America
2Department of Psychiatry,
3Department of Pediatrics, Lady Hardinge Medical College, New Delhi, India

Chapter 10. Cannabis: Current concepts and conundrums
Donald E Geydanus, MD, DrHC (Athens) and Maria Demma Cabral, MD
Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker
MD School of Medicine, Kalamazoo, Michigan, United States of America

Chapter 11. Psychosocial treatments for substance use disorders
Muhammad Ather1, MRCPsych, Nehdia Hashemi2, MD, Ahsan Nazeer1, MD and Muhammad Waqar Azeem1, MD
1Department of Psychiatry, Sidra Medicine, Doha, Qatar
2Department of Clinical Academic Sciences, Qatar University School of Medicine, Doha, Qatar

Chapter 12. Substance use disorders in adolescents: Pharmacologic management
Donald E Greydanus, MD, DrHC(Athens)
Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, United States of America

Chapter 13. Use of pharmacologic agents for smoking cessation
Dilip R Patel, MD, MBA, MPH, Danielle Hirsch, MD, MPH, and Kimberly Wells, MD
Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, United States of America

Section Three:  Selective concepts of management

Chapter 14. Psychotherapeutic intervention with children and adolescents
Nehdia Hashemi, MD1, Salma Malik, MD2, Nazish Imran, FRPsych3, Muhammad Zeeshan, MD4
and Ahsan Nazeer5, MD
1Western Michigan University, Homer Stryker MD School of Medicine, Kalamazoo, Michigan 2Institute of Living/Hartford Healthcare, Hartford, Connecticut, United States, 3King Edward Medical University, Lahore, Pakistan, and
4Rutgers New Jersey Medical School, Newark, New Jersey, The United States of America
5Sidra Medicine/Weill Cornell Medicine, Doha, Qatar

Chapter 15. Behavioral and cognitive behavioral therapies
Stephen McLearie1, MRCPsych, Nehdia Hashemi2, MD, Madeeha Kamal1, FRCP, Nazish Imran3, MRCPsych, Sadiq Naveed4, MD, Muhammad Waqar Azeem1, MD, and Ahsan Nazeer1,*, MD
1Sidra Medicine/Weill Cornell Medicine, Doha, Qatar, 2Western Michigan University, Homer Stryker MD School of Medicine, Kalamazoo, Michigan,
3King Edward Medical University, Lahore, Pakistan and Institute of Living/Hartford Healthcare, Hartford, Connecticut, USA

Chapter 16. Introduction to pediatric psychopharmacology
Muhammad Zeshan1, MD, Fauzia Arain2, MD, Aiman Tohid3, MD, MPH, Muhammad Youshay Jawad4, MBBS, Ali Imam Awan5, MD, and Haroon Arain6, BS
1Department of Psychiatry, Rutgers New Jersey Medical School, Newark, New Jersey,
Unites States of America
2Child and Adolescent Psychiatry, Icahn School of Medicine at Mount Sinai, BronxCare Health System, New York, United States of America
3Department of Psychiatry, University of Southern California, Los Angeles, California, United States of America
4King Edward Medical University, Lahore, Pakistan
5Department of Psychiatry, Services Institute of Medical Sciences, Lahore, Pakistan and 6Columbia University, New York, United States of America

Section Four: Acknowledgements

About the editors

About the Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine (WMED), Kalamazoo, Michigan, United States of America

Department of Psychiatry, Division of Child and Adolescent Psychiatry, Sidra Medicine, Doha, Qatar

About the National Institute of Child Health and Human Development in Israel, Jerusalem, Israel

Section Five: Index

Index